Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-11-08
2005-11-08
Shameem, Golam M. M. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S478000, C548S469000
Reexamination Certificate
active
06962940
ABSTRACT:
Stereomerically pure (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, substantially free of its (−) isomer, and prodrugs, metabolites, polymorphs, salts, solvates, hydrates, and clathrates thereof are discussed. Also discussed are methods of using and pharmaceutical compositions comprising the (+) enantiomer of 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the reduction of levels of TNF-α or the inhibition of PDE4.
REFERENCES:
patent: 3031450 (1962-04-01), Fischer et al.
patent: 3322755 (1967-05-01), Roch et al.
patent: 3920636 (1975-11-01), Takahashi et al.
patent: 4001237 (1977-01-01), Partyka et al.
patent: 4001238 (1977-01-01), Partyka et al.
patent: 4047404 (1977-09-01), Hayashi
patent: 4060615 (1977-11-01), Matier et al.
patent: 4101548 (1978-07-01), Crenshaw et al.
patent: 4162316 (1979-07-01), Nishimura et al.
patent: 4209623 (1980-06-01), Juby
patent: 4880810 (1989-11-01), Lowe, III
patent: 4885301 (1989-12-01), Coates
patent: 5147875 (1992-09-01), Coates et al.
patent: 5354571 (1994-10-01), Morikawa et al.
patent: 5401774 (1995-03-01), Pamukcu et al.
patent: 5439895 (1995-08-01), Lee et al.
patent: 5488055 (1996-01-01), Kumar et al.
patent: 5608914 (1997-03-01), Keesler
patent: 5614530 (1997-03-01), Kumar et al.
patent: 5614627 (1997-03-01), Takase et al.
patent: 5658940 (1997-08-01), Muller et al.
patent: 5698579 (1997-12-01), Muller
patent: 5703098 (1997-12-01), Muller et al.
patent: 5710170 (1998-01-01), Guay et al.
patent: 5728844 (1998-03-01), Muller et al.
patent: 5728845 (1998-03-01), Muller et al.
patent: 5736570 (1998-04-01), Muller et al.
patent: 5798373 (1998-08-01), Warrellow
patent: 5801195 (1998-09-01), Muller et al.
patent: 5849770 (1998-12-01), Head et al.
patent: 5877200 (1999-03-01), Muller
patent: 5891896 (1999-04-01), Warrellow et al.
patent: 6011060 (2000-01-01), Laurent et al.
patent: 6020339 (2000-02-01), Perrier et al.
patent: 6020358 (2000-02-01), Muller et al.
patent: 6034089 (2000-03-01), Han et al.
patent: 6046221 (2000-04-01), Muller et al.
patent: 6069156 (2000-05-01), Oku et al.
patent: 6162830 (2000-12-01), Connor et al.
patent: 6166041 (2000-12-01), Cavalla et al.
patent: 6177471 (2001-01-01), Menander et al.
patent: 6204275 (2001-03-01), Friesen et al.
patent: 6218400 (2001-04-01), Daugan et al.
patent: 6300335 (2001-10-01), Campbell et al.
patent: 6316472 (2001-11-01), Frenette et al.
patent: 6333354 (2001-12-01), Schudt
patent: 0 347 146 (1989-06-01), None
patent: 0 349 239 (1989-06-01), None
patent: 0 351 058 (1989-06-01), None
patent: 0 352 960 (1989-07-01), None
patent: 0 395 328 (1990-04-01), None
patent: 0 428 268 (1990-10-01), None
patent: 0 463 756 (1991-06-01), None
patent: 0 526 004 (1992-07-01), None
patent: 0 607 439 (1992-09-01), None
patent: 0 722 937 (1996-01-01), None
patent: 0 722 943 (1996-01-01), None
patent: 0 722 944 (1996-01-01), None
patent: 2 063 249 (1980-09-01), None
patent: WO 93/07149 (1993-04-01), None
patent: WO 93/12095 (1993-06-01), None
patent: WO 94/01728 (1994-01-01), None
patent: WO 94/05661 (1994-03-01), None
patent: WO 94/29277 (1994-12-01), None
patent: WO 95/19978 (1995-07-01), None
patent: WO 96/32379 (1996-10-01), None
patent: WO 97/03070 (1997-01-01), None
patent: WO 97/03675 (1997-02-01), None
patent: WO 97/03985 (1997-02-01), None
patent: WO 97/24334 (1997-07-01), None
patent: WO 98/06722 (1998-02-01), None
patent: WO 98/08848 (1998-03-01), None
patent: WO 98/14448 (1998-04-01), None
patent: WO 98/16521 (1998-04-01), None
patent: WO 98/17668 (1998-04-01), None
patent: WO 98/23597 (1998-06-01), None
patent: WO 98/38168 (1998-09-01), None
patent: WO 99/06041 (1999-02-01), None
U.S. Appl. No. 60/454,155, G. Muller et al., filed Mar. 12, 2003.
U.S. Appl. No. 60/454,159, G. Muller et al., filed Mar. 12, 2003.
U.S. Appl. No. 60/438,448, G. Muller et al., filed Jan. 7, 2003.
U.S. Appl. No. 60/436,975, G. Muller et al., filed Dec. 30, 2002.
U.S. Appl. No. 60/366,515, G. Muller et al., filed Mar. 20, 2002.
Au et al., 1998,Brit. J. Pharm.123:1260-1266.
Baehr et al., 1979,J. Biol. Chem.254:11669.
Baughman et al., 1990,J. Lab. Clin. Med.115:36-42.
Beavo and Reifsnyder,Trends in Pharm.,11, 150-55, 1990.
Bissonnette et al., 1989,Inflammation13:329-339.
Bloom and Beavo 1996,Proc. Natl. Acad. Sci. USA93:14188-14192.
Brackeen, M.F. et al., 1995, “Design and synthesis of conformationally constrained analogues of 4-(3-butoxy-4-methoxybenzyl) imidazolidin-2-one (Ro 20-1724) as potent inhibitors of cAMP-specific phosphodiesterase”,J. Med. Chem.38:4848-54.
Carstensen, Jens T., 1995,Drug Stability: Principles&Practice, 2nd ed., Marcel Dekker, New York, NY pp. 379-380.
Casini et al., 1964, Farmaco Ed. Sci. 19:563.
Clouse et al., 1989,J. Immunol.142:431-438.
Derian et al., 1995,J. Immunol.154:308-317.
Duh et al., 1989,Proc. Nat. Acad. Sci.86:5974-5978.
Featherstone, R.L., et al., 2000, “Comparison of phosphodiesterase inhibitors of differing isoenzyme selectivity added to St. Thomas' hospital cardioplegic solution used for hypothermic preservation of rat lungs”, Am. J. Respir. Crit. Care Med. 162:850-6.
Gillespie et al., 1989,Mol. Pharm.36:773.
Hidaka and Asano 1976,Biochem. Biophys. Acta429:485.
Hinshaw et al. 1990,Circ. Shock30:2797-292.
Holler et al., 1990,Blood75:1101-1016.
Johnson et al., 1989,Endocrinology124:1424-1427.
List et al., 1990,J. Clin. Oncol.8:1424.MDS.
Merck Manual (1999) 17thed., 953.
Monté et al., 1990,Blood79:2670.
Muller, George, et al., 1999,Bioorganic&Medicinal Chemistry Letters9; pp. 1625-1630.
Muller et al., 1998,Bioorg.&Med Chem Lett.8:2669-2674.
Muller, et al., 1996,J. Med. Chem.39:3238.
Nicholson et al., 1991,Trends Pharmaco. Sci.12:19.
Shealy et al., 1965, “D-and L-thalidomide.”Chem. Indus.12;24:1030-1.
Tierney, et al.,ed., 1998, Current Medical Diagnosis & Treatment, 37thed., Appleton & Lange, pp. 499.
Verghese, et al.,Journal of Pharmacology and Experimental Therapeutics, 272(3), 1313-1320, 1995.
Van Dullemen et al., 1995,Gastroenterology, 109:129-135.
Wilen, S.H., et al., 1977,Tetrahedron33:2725.
Wilen, S.H., 1972,Tables of Resolving Agents and Optical Resoutions(E.L. Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN) p. 268.
Wolff, Manfred E.,ed., Burger's Medicinal Chemistry and Drug Discovery, 5thed. 1995 172-178, 949-982.
Akazome, M. et al., 1997, “Asymmetric recognition of 1-arylethylamines by (R)-phenylglycyl-(R)-phenylglycine and its mechanism,” Tetrahedron: Asymmetry, Elsevier Scince Publishers, Amsterdam, NL, 8(14):2331-2336.
Luke, G.P. et al., 1999, “Synthesis of(S)-5-(1-aminoethyl)-2-(cyclohexylmethoxy) benzamide,” Tetrahedron: Asymmetry, Elsevier Science Publishers, Amsterdam, NL, 10(22):4393-4403.
Ge Chuansheng
Man Hon-Wah
Muller George W.
Schafer Peter H.
Celgene Corporation
Day Jones
Shameem Golam M. M.
LandOfFree
(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3482498